BR112017026853A2 - composição de ação prolongada - Google Patents

composição de ação prolongada

Info

Publication number
BR112017026853A2
BR112017026853A2 BR112017026853A BR112017026853A BR112017026853A2 BR 112017026853 A2 BR112017026853 A2 BR 112017026853A2 BR 112017026853 A BR112017026853 A BR 112017026853A BR 112017026853 A BR112017026853 A BR 112017026853A BR 112017026853 A2 BR112017026853 A2 BR 112017026853A2
Authority
BR
Brazil
Prior art keywords
composition
long acting
days
acting composition
liraglutide
Prior art date
Application number
BR112017026853A
Other languages
English (en)
Inventor
Jaysingh Khopade Ajay
Halder Arindam
Patel Vivek
Original Assignee
Sun Pharma Advanced Research Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Company Limited filed Critical Sun Pharma Advanced Research Company Limited
Publication of BR112017026853A2 publication Critical patent/BR112017026853A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se a uma composição de ação prolongada que compreende, uma quantidade terapeuticamente eficaz de liraglutida, um copolímero de bloco ou de enxerto que compreende frações hidrófilas ou hidrófobas ou misturas das mesmas, pelo menos um anfipático, e um veículo aquoso, em que a composição é na forma de um gel que é tornado capaz de ser injetado quando forçado através de uma agulha por meio de um êmbolo. a composição proporciona controle eficaz da glicose no sangue por cerca de 6 dias a cerca de 14 dias após uma única administração a um indivíduo em necessidade da mesma, particularmente por cerca de uma semana.
BR112017026853A 2015-06-16 2016-06-16 composição de ação prolongada BR112017026853A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1567MU2015 2015-06-16
PCT/IN2016/050185 WO2016203495A1 (en) 2015-06-16 2016-06-16 Long acting liraglutide compositions

Publications (1)

Publication Number Publication Date
BR112017026853A2 true BR112017026853A2 (pt) 2018-08-14

Family

ID=57546764

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017026853A BR112017026853A2 (pt) 2015-06-16 2016-06-16 composição de ação prolongada

Country Status (10)

Country Link
US (1) US20180169010A1 (pt)
EP (1) EP3310335A4 (pt)
JP (1) JP2018517745A (pt)
CN (1) CN107708667A (pt)
AU (1) AU2016280873A1 (pt)
BR (1) BR112017026853A2 (pt)
CA (1) CA2989283A1 (pt)
MX (1) MX2017016418A (pt)
RU (1) RU2018101070A (pt)
WO (1) WO2016203495A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
EP3802625B1 (en) * 2018-06-11 2022-04-20 Universidade de Coimbra Photopolymerized biodegradable copolymer formulations for biomedical applications
CN109010310B (zh) * 2018-08-16 2019-05-24 中山万汉制药有限公司 包含奥利司他与glp-1受体激动剂的组合物及其用途
KR20210099553A (ko) * 2018-09-06 2021-08-12 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 주사 가능한 서방형 항생 제제
WO2023189273A1 (ja) * 2022-03-28 2023-10-05 富士フイルム株式会社 生体用組成物
WO2023189270A1 (ja) * 2022-03-28 2023-10-05 富士フイルム株式会社 生体用組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1817048B1 (en) * 2004-11-12 2014-02-12 Novo Nordisk A/S Stable formulations of insulinoptropic peptides
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CN102085355B (zh) * 2011-01-27 2012-11-28 蚌埠丰原涂山制药有限公司 一种利拉鲁肽长效微球注射剂及其制备方法
WO2012177929A2 (en) * 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
CN104840415B (zh) * 2014-02-19 2019-03-15 香港浸会大学 含有降血糖活性成分的长效控释脂质体凝胶组合物及其制备方法

Also Published As

Publication number Publication date
EP3310335A1 (en) 2018-04-25
US20180169010A1 (en) 2018-06-21
EP3310335A4 (en) 2019-02-06
MX2017016418A (es) 2018-05-02
AU2016280873A1 (en) 2018-01-04
RU2018101070A (ru) 2019-07-16
CA2989283A1 (en) 2016-12-22
CN107708667A (zh) 2018-02-16
WO2016203495A1 (en) 2016-12-22
JP2018517745A (ja) 2018-07-05

Similar Documents

Publication Publication Date Title
BR112017026853A2 (pt) composição de ação prolongada
BR112021019731A2 (pt) Composições para tratamento bucal para liberação de agente ativo
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
PE20211202A1 (es) Composiciones de glp-1 y sus usos
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
BR112016029713A8 (pt) uso de uma carboximetilcelulose reticulada e uso de um agente gelificante
AR105712A1 (es) Composiciones de insulina de rápida acción
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
BR112018003845A2 (pt) auxiliares cirúrgicos com medicamentos afetados por materiais ativadores
BR112017021311A2 (pt) composições farmacêuticas para terapia de combinação
BR112017014332A2 (pt) métodos de tratamento de doenças retinianas
UY38428A (es) Nuevos compuestos antihelmínticos
CL2015002940A1 (es) Usos terapéuticos de empaglifozina.
BR112014002788A2 (pt) dispositivos de oclusão baseados em polímeros, sistemas e métodos
BR112016002233A2 (pt) composições de adoçante
BR112017020948A2 (pt) composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão
BR112015017246A8 (pt) composição farmacêutica aquosa, seu uso e seringa
BR112015023481A8 (pt) projeto de perfil de liberação de fármaco de controle via composição de lipossomo em ambos os compartimentos aquosos e não-aquosos
BR112016001544A2 (pt) composições farmacêuticas para injeção intraocular compreendendo agentes anti-bacteriano e anti-inflamatório, seu método de preparação, kit farmacêutico e uso dos referidos agentes no preparo das referidas composições farmacêuticas
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
BR112017008805A2 (pt) tratamento de córnea usando laminina
BR112018069591A2 (pt) gel viscoelástico e método para o controle de níveis de glicose no sangue

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]